PAYO vs. MEDP, FOUR, HQY, BILI, WPP, LYFT, MARA, SEZL, AMTM, and ETSY
Should you be buying Payoneer Global stock or one of its competitors? The main competitors of Payoneer Global include Medpace (MEDP), Shift4 Payments (FOUR), HealthEquity (HQY), Bilibili (BILI), WPP (WPP), Lyft (LYFT), Marathon Digital (MARA), Sezzle (SEZL), Amentum (AMTM), and Etsy (ETSY). These companies are all part of the "business services" industry.
Payoneer Global vs. Its Competitors
Medpace (NASDAQ:MEDP) and Payoneer Global (NASDAQ:PAYO) are both mid-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
In the previous week, Medpace had 16 more articles in the media than Payoneer Global. MarketBeat recorded 19 mentions for Medpace and 3 mentions for Payoneer Global. Medpace's average media sentiment score of 0.96 beat Payoneer Global's score of 0.72 indicating that Medpace is being referred to more favorably in the media.
78.0% of Medpace shares are owned by institutional investors. Comparatively, 82.2% of Payoneer Global shares are owned by institutional investors. 20.3% of Medpace shares are owned by insiders. Comparatively, 2.6% of Payoneer Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Medpace has higher revenue and earnings than Payoneer Global. Payoneer Global is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Medpace has a net margin of 19.31% compared to Payoneer Global's net margin of 11.32%. Medpace's return on equity of 54.36% beat Payoneer Global's return on equity.
Medpace has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Payoneer Global has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
Medpace presently has a consensus target price of $344.82, suggesting a potential upside of 6.59%. Payoneer Global has a consensus target price of $10.44, suggesting a potential upside of 61.07%. Given Payoneer Global's stronger consensus rating and higher probable upside, analysts clearly believe Payoneer Global is more favorable than Medpace.
Summary
Medpace beats Payoneer Global on 12 of the 17 factors compared between the two stocks.
Get Payoneer Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PAYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Payoneer Global Competitors List
Related Companies and Tools
This page (NASDAQ:PAYO) was last updated on 7/12/2025 by MarketBeat.com Staff
